Sociedad Americana de Hirudoterapia

John Berry Haycraft

1857-1922 · British (Scottish) · biochemistry

Biographical referenceHistorical record
19th c.biochemistry

Edinburgh physiologist who discovered hirudin in 1884, founding the modern molecular pharmacology of leech saliva.

Profile

Life years
1857-1922
Nationality
British (Scottish)
Era
19th century
Primary field
biochemistry

Institutional Affiliations

  • University of Edinburgh Medical School
  • University College Cardiff (Department of Physiology, Chair 1893-1922)
  • Royal Society of London (Fellow)

Key Contributions

  • Isolated the anticoagulant principle from Hirudo medicinalis salivary glands in 1884 and named it 'hirudin' — the first identified leech bioactive compound.
  • Demonstrated that hirudin blocks blood coagulation in vitro through a direct enzymatic interaction, decades before thrombin was characterized.
  • Established Edinburgh's University Physiological Laboratory as the cradle of leech pharmacology research.
  • Published the foundational 1884 paper 'On the Action of a Secretion Obtained from the Medicinal Leech on the Coagulation of the Blood,' cited by every hirudin paper since.
  • Trained a generation of British physiologists who continued anticoagulant research into the 20th century.

Importance to Hirudotherapy

John Berry Haycraft's 1884 isolation of hirudin from medicinal leech salivary glands is the single most important event in the molecular history of hirudotherapy. Before Haycraft, the leech was a folk-medicine instrument whose action was attributed to vague 'humoral' or mechanical effects. By demonstrating that a specific chemical secretion was responsible for the prolonged bleeding observed after a leech bite — and that this secretion could be extracted, concentrated, and applied to blood in vitro — Haycraft transformed hirudotherapy from empirical practice into experimental pharmacology. His methodological choice mattered as much as his discovery. Haycraft used Edinburgh's then-novel saline-perfusion technique to flush the leech's anterior salivary glands, then tested the extract against fibrinogen-rich plasma. The resulting non-clotting phenomenon was reproducible, dose-dependent, and species-specific. He correctly inferred (without understanding thrombin) that the active principle interfered with the final step of fibrin formation. Modern crystallographic work — Stone & Hofsteenge in 1986, the PDB structures 1HRT and 4HTC — confirmed Haycraft's intuition with atomic precision: hirudin binds thrombin's active and exosite-1 surfaces with sub-picomolar affinity. Hirudin seeded an entire anticoagulant drug class. Two recombinant hirudin analogs reached the clinic — desirudin (FDA-approved, marketed) and lepirudin (approved 1998, voluntarily withdrawn in 2012) — and the rationally designed synthetic peptide bivalirudin (marketed) was built directly on hirudin's bivalent thrombin-binding architecture. Later synthetic small-molecule inhibitors such as dabigatran were inspired by the same thrombin-inhibition principle Haycraft uncovered, not derived from hirudin itself. The American Society of Hirudotherapy considers him the patron of evidence-based leech medicine — a 19th-century scientist whose careful protocols made it impossible for later generations to dismiss leech therapy as superstition.

Key Publications

  1. On the Action of a Secretion Obtained from the Medicinal Leech on the Coagulation of the Blood · Proceedings of the Royal Society of London (1884)
  2. Über die Einwirkung eines Sekretes des officinellen Blutegels auf die Blutgerinnung · Archiv für Experimentelle Pathologie und Pharmakologie (1884)
  3. On the Objection to Pain (Smithsonian Lecture) · Nature (1895)

Notable Quotes

The secretion of the leech possesses the singular power of preventing the coagulation of the blood with which it is mixed, even in extremely small doses, and this property is not destroyed by boiling.

Haycraft JB, Proc R Soc Lond, 1884

The leech is, perhaps, the only animal known to us which produces a substance that, having entered the body of another animal, opposes itself to one of that animal's most vital chemical processes — the act of coagulation.

Haycraft JB, Edinburgh Med J, 1884

External Resources

Influenced Research

Compounds and research areas tracing back to this figure's contributions:

Related Figures

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.